– PRECIPHOS –
Promote precision medicine in Cardiovascular Diseases
Preciphos is developing an innovative approach combining the use of new diseases-based biomarkers with the mean of a non-invasive, multiplex and easy-to-use diagnostic device developed by the Swiss Institute of Technology Zürich (Prof. J. Voeroes & Dr. Victoria De Lange) for the diagnosis and prognosis of cardiovascular diseases.
These biomarkers were already determined by means of a qualitative assay in 7,000 asymptomatic subjects and in patients suffering of a cardiovascular disease by the University Hospital of Geneva (Prof. N. Vuilleumier & Dr. N. Satta-Poschung). The results available so far, demonstrated that the precision medical-approach is key for the early identification of subjects at risk of cardiovascular diseases that could benefit from anti-inflammatory and/or immune treatments. This will make possible to slacken the chronic disease evolution thus improving the patient outcome while decreasing the associated healthcare-costs.
We are looking for a 8.5 MM Euros funding in order to speed up the development of our technologies aiming at initiating sales as RUO products by the end of 2022 and getting a positive EBIT late 2025. Preciphos intends to enter in a merging deal (several contacts and
collaboration are ongoing) or to initiate an IPO in 2026.
Share Capital: € 127,759.- on September 2020
Challenge & Value Proposition
Portable IVD devices to be used in precision medicine
Preciphos supports physicians in promoting precision medicine and for this purpose proposes portable multiplex analysis devices for in-vitro diagnostics in order to quantitate complex bio-molecules that aims (i) at optimizing the individual stratification of cardiovascular risk in primary prevention and (ii) at reducing the residual risk (1 in 5 patients) of patient death in secondary prevention
Developing portable IVD devices to be used in precision medicine and make In Vitro Diagnostic (IVD) testing.
This device is capable to simultaneously determine at the moment, up to 8 biomolecules using 10-μL whole blood.
Develop and market a multiplex, portable, user-friendly and cost-effective analytical device, based on a patented miniaturized immunological technology.
Enable the simultaneous determination of multiple autoimmune and inflammatory-related biomarkers associated with cardio-vascular diseases, meant to optimize individual CV risk stratification in primary prevention and patient CV residual risk management in secondary prevention.
Who we are
Who We Are
Preciphos wants to help doctors develop precision medicine with the aim of reducing care costs
The company focuses on the measurement of a proprietary panel of autoimmune and inflammatory biomarkers mediating pro-atherogenic processes related to the acute clinical manifestation of atherosclerotic cardiovascular diseases (ASCVD). This new medical approach will be key to improve the identification of specific patients’ subset at high CV risk that could benefit from anti-inflammatory and/or immunomodulatory treatments. It will further contribute to the development of precision medicine in ASCVD which is still the leading cause of death in developed and developing countries.
We wish to contribute to the development of precision medicine in ASCVD, which remains the leading cause of death in the world
HOW IT WORK'S ?
Download our presentation to understand our technology
Meet Our Team
CChem. | M.R.S.C.
– Get a call –
Don’t Hesitate To Contact With Us
Do You Have Any Questions?
For information and documentation relating to our products or for a specific request, do not hesitate to contact our team
: 8 place de l’hôpital – 67000 Strasbourg